Correspondence to Dr Dimitrios T Boumpas, Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, "Attikon" University Hospital, Joint Academic Rheumatology Program, National ...

Correspondence to Dr Antonis Fanouriakis, Rheumatology and Clinical Immunology Unit, “Attikon” University Hospital, Athens 12462, Greece; afanour{at}med.uoa.gr Our objective was to update the EULAR ...

Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...

Objective To assess the efficacy and safety of the type I interferon receptor antibody, anifrolumab, in patients with active, biopsy-proven, Class III/IV lupus nephritis. Methods This phase II ...

Correspondence to Eng M Tan, The Scripps Research Institute, La Jolla, CA 92037, USA; emtan{at}scripps.edu Henry Kunkel was born in Brooklyn, New York in 1916. He died in 1983 at the early age of 67.

Background: Systemic lupus erythematosus (SLE) is a multiple systemic autoimmune disease and its pathogenesis is still not fully understanding. In recent years, there has been reports on the ...

Backgroundand objectives Mesenchymal stem or stromal cells (MSC) are multipotent cells that can differentiate into different lineages, particularly osteoblasts and chondrocytes. The differentiation ...

Correspondence to Dr Elisa Fernandez-Cooke, Department of Pediatrics Infectious Diseases, Doce de Octubre University Hospital, Madrid 28041, Spain; elisafcooke{at}gmail.com Kawasaki disease (KD) is a ...

Background We have often found that markers of inflammation such as elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) do not match in the routine clinical management of ...

1 Clinical Epidemiology Research Unit, Hospital Especialidades, Centro Médico Nacional Instituto Mexicano del Seguro Social, Mexico 2 Internal Medicine Department, Centro Médico Nacional Instituto ...

Objective Macrophage activation syndrome (MAS) is a life-threatening complication of systemic juvenile idiopathic arthritis (sJIA) characterised by a vicious cycle of immune amplification that can ...

Background The presence of rheumatoid factor (RF) is associated with progression of joint damage in patients with rheumatoid arthritis (RA). RF levels may change during the course of therapy 1, but it ...